Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Buy
65
VTYX Quote, Financials, Valuation and Earnings
Last price:
$3.27
Seasonality move
:
59.51%
Day range:
$2.99 - $3.17
52-week range:
$0.78 - $3.39
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.96x
Volume:
1M
Avg. volume:
2M
1-year change:
-2.19%
Market cap:
$222.7M
Revenue:
--
EPS (TTM):
-$1.75
Analysts' Opinion
-
Consensus RatingVentyx Biosciences has received a consensus rating of Buy. The company's average rating is a Buy based on 5 Buy ratings, 2 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $12.00, Ventyx Biosciences has an estimated upside of 283.39% from its current price of $3.13.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $2.00 representing 100% downside risk from its current price of $3.13.
Fair Value
-
According to the consensus of 7 analysts, Ventyx Biosciences has 283.39% upside to fair value with a price target of $12.00 per share.
VTYX vs. S&P 500
-
Over the past 5 trading days, Ventyx Biosciences has overperformed the S&P 500 by 30.33% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Ventyx Biosciences does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Ventyx Biosciences has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Ventyx Biosciences reported revenues of --.
Earnings Growth
-
Ventyx Biosciences has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Ventyx Biosciences reported earnings per share of -$0.39.
Enterprise value:
-6.1M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
0.06x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$132.9M | -$207.2M | -$136.8M | -$41.8M | -$30.1M | |
| EBITDA | -$132.4M | -$206M | -$135.5M | -$41.4M | -$29.7M | |
| Diluted EPS | -$2.28 | -$3.24 | -$1.75 | -$0.62 | -$0.39 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | $257.5M | $387.1M | $319.8M | $242.6M | |
| Total Assets | -- | $278M | $389.2M | $332.1M | $253.5M | |
| Current Liabilities | -- | $17.8M | $16.5M | $14.5M | $12.4M | |
| Total Liabilities | -- | $18.8M | $17.6M | $25.1M | $21.8M | |
| Total Equity | -- | $259.1M | $371.6M | $307M | $231.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$117M | -$183.2M | -$109M | -$47.6M | -$25.7M | |
| Cash From Investing | -$77.3M | $161.6M | -$30.9M | $41.8M | $26.4M | |
| Cash From Financing | $216.3M | $100.9M | $25.9M | $96.2M | -- | |
| Free Cash Flow | -$117.3M | -$183.9M | -$109M | -$47.8M | -$25.7M | |
VTYX
Sector
Market Cap
$222.7M
$34.4M
Price % of 52-Week High
92.33%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-2.19%
-37.36%
Beta (5-Year)
--
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$2.63
200-day SMA
Buy
Level
$1.92
Bollinger Bands (100)
Buy
Level
1.11 - 2.21
Chaikin Money Flow
Buy
Level
5.4M
20-day SMA
Buy
Level
$2.41
Relative Strength Index (RSI14)
Buy
Level
72.16
ADX Line
Buy
Level
39.56
Williams %R
Sell
Level
-3.2787
50-day SMA
Buy
Level
$2.03
MACD (12, 26)
Buy
Level
0.79
25-day Aroon Oscillator
Buy
Level
32
On Balance Volume
Neutral
Level
9.2M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (2)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.
Stock Forecast FAQ
In the current month, VTYX has received 5 Buy ratings 2 Hold ratings, and 0 Sell ratings. The VTYX average analyst price target in the past 3 months is $12.00.
-
Where Will Ventyx Biosciences Stock Be In 1 Year?
According to analysts, the consensus estimate is that Ventyx Biosciences share price will rise to $12.00 per share over the next 12 months.
-
What Do Analysts Say About Ventyx Biosciences?
Analysts are divided on their view about Ventyx Biosciences share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Ventyx Biosciences is a Sell and believe this share price will drop from its current level to $2.00.
-
What Is Ventyx Biosciences's Price Target?
The price target for Ventyx Biosciences over the next 1-year time period is forecast to be $12.00 according to 7 Wall Street analysts, 5 of them rate the stock a Buy, 0 rate the stock a Sell, and 2 analysts rate the stock a Hold.
-
Is VTYX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Ventyx Biosciences is a Buy. 5 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of VTYX?
You can purchase shares of Ventyx Biosciences via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Ventyx Biosciences shares.
-
What Is The Ventyx Biosciences Share Price Today?
Ventyx Biosciences was last trading at $3.27 per share. This represents the most recent stock quote for Ventyx Biosciences. Yesterday, Ventyx Biosciences closed at $3.13 per share.
-
How To Buy Ventyx Biosciences Stock Online?
In order to purchase Ventyx Biosciences stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
